Endometrial Stromal Sarcoma (ESS) Explained

What Is Endometrial Stromal Sarcoma?

The lining of the uterus — the endometrium — is made of two parts: the glands that thicken and shed during a period, and the stroma, a mesh of supporting connective tissue that holds those glands together. Endometrial stromal sarcoma is a cancer of that stroma. Because it is a sarcoma (a cancer of connective tissue) rather than a carcinoma (a cancer of glands or skin-type lining), it sits within the family of uterine sarcoma — and is quite separate from the far more common endometrial (lining) carcinoma. You can see how it fits alongside the other connective-tissue cancers on our sarcoma — overview hub.

ESS is rare. Uterine sarcomas as a whole make up only a few percent of all uterine cancers, and endometrial stromal sarcoma is one subtype within that small group. Most cases are diagnosed in women between their late 30s and 50s — often, importantly, in women who are still pre-menopausal, which is one reason fertility and ovarian preservation come up so often in conversations about this disease.

Modern pathology divides endometrial stromal tumours into clearly separate groups. The benign end of the spectrum is the endometrial stromal nodule, which does not invade and is cured by removal. The cancers are low-grade ESS and high-grade ESS, and beyond them sits undifferentiated uterine sarcoma — a high-grade tumour so disorganised that it has lost the features that would let a pathologist call it ESS at all. Getting this classification right is the foundation of every treatment decision, which is why a specialist pathology re-read is the first thing CION does with any ESS report.

Low-Grade ESS vs High-Grade ESS: The Difference That Matters

If you remember only one thing from this page, make it this: low-grade and high-grade ESS are two different diseases that happen to share a name. They look different under the microscope, they are driven by different genetic changes, they grow at different speeds, and — crucially — they respond to different treatments. Confusing the two leads to the wrong treatment, so the grade is always confirmed before anything is decided.

Why low-grade ESS is hormone-driven

Most low-grade ESS tumours carry oestrogen and progesterone receptors, meaning the body's own hormones can fuel their growth. This single fact shapes treatment: removing the ovaries (the main source of oestrogen) is part of surgery, and oestrogen-blocking drugs are used afterwards to keep the disease in check. It is also why anything that raises oestrogen — such as hormone-replacement therapy or tamoxifen — is generally avoided in women who have had low-grade ESS.

Why high-grade ESS needs a different plan

High-grade ESS usually does not carry those hormone receptors, so endocrine therapy is far less useful. Instead, after surgery, the tumour board weighs radiation to the pelvis and/or chemotherapy, guided by stage and the specific genetic rearrangement found on testing. This is why two women with "ESS" on their report can be offered completely different treatment — the word on the page is the same, but the disease underneath is not.

Symptoms: What Endometrial Stromal Sarcoma Feels Like

ESS does not announce itself with a single dramatic symptom. Its warning signs overlap heavily with common, benign gynaecological conditions — which is part of why it is so often missed at first. The pattern worth taking seriously is abnormal uterine bleeding that does not fit your normal cycle, especially when it persists or worsens.

• Abnormal uterine bleeding — heavy, prolonged, irregular, or between-period bleeding that is new for you
• Postmenopausal bleeding — any bleeding after menopause should always be investigated
• Pelvic pain or pressure — a dull ache or a sense of fullness low in the abdomen
• An enlarging uterus or mass — sometimes mistaken for a rapidly growing fibroid
• A "fibroid" that keeps growing — particularly one that grows quickly or grows after menopause

None of these symptoms means you have ESS — fibroids, hormonal changes and polyps cause the very same complaints far more often. But because the symptoms are shared, the only safe response to persistent abnormal bleeding or a fast-growing pelvic mass is proper investigation: a scan, and where indicated, a tissue sample. The danger is assuming a growing mass is "just a fibroid" without ever confirming it.

How Endometrial Stromal Sarcoma Is Diagnosed and Staged

ESS is notoriously difficult to diagnose before surgery, because it can look exactly like a fibroid on imaging and because a routine endometrial biopsy may not reach the stromal tumour deep in the uterine wall. A confident diagnosis usually comes from a combination of imaging, tissue, and — most importantly — specialist pathology.

Step 1 — Pelvic MRI

MRI is the best scan for looking at a uterine mass. It shows the size and exact location of the tumour, whether it is confined to the uterus or extending beyond it, and features that raise suspicion for a sarcoma rather than a benign fibroid. While no scan can prove ESS on its own, a worrying MRI is often what redirects a "routine fibroid" plan toward a cancer-safe surgical approach.

Step 2 — Tissue Sampling and Immunohistochemistry

A definitive diagnosis needs tissue. Sometimes this comes from an endometrial biopsy or a dilatation and curettage; more often, the diagnosis is only confirmed on the full uterus after hysterectomy. Whatever the source, the pathologist uses immunohistochemistry — special stains for markers such as CD10, oestrogen and progesterone receptors — and, where needed, molecular testing for the characteristic gene fusions. This is what separates low-grade ESS from high-grade ESS, from undifferentiated sarcoma, and from a benign stromal nodule. Because the subtype changes the entire treatment plan, CION routinely arranges a specialist sarcoma-pathology re-read of any outside report.

Step 3 — Staging

Uterine sarcomas are staged using the FIGO system, which describes how far the disease has spread: Stage I is confined to the uterus, Stage II involves the cervix or beyond into the pelvis, Stage III reaches abdominal tissues or pelvic lymph nodes, and Stage IV involves the bladder, bowel, or distant organs such as the lungs. A CT scan of the chest, abdomen and pelvis is used to check for spread. Stage, alongside grade, is the strongest guide to both treatment and outlook.

How Endometrial Stromal Sarcoma Is Treated

Treatment is built around surgery, then tailored by grade. Here is how the gynae-oncology tumour board at CION approaches each piece.

A question that comes up often, especially among younger women, is fertility. Because the standard operation removes the uterus and ovaries, it ends fertility — but in carefully selected, very early low-grade cases, fertility-sparing or ovary-sparing approaches are sometimes discussed. These are individualised decisions that must be weighed against recurrence risk and made only with a gynae-oncologist, never assumed. If you want to understand how ESS sits within the wider family of uterine sarcoma and how its treatment compares with other subtypes, that overview is a useful companion to this page.

Prognosis, Recurrence and Long-Term Follow-Up

Outlook in ESS depends most on two things: the grade and the stage at diagnosis. Early-stage low-grade ESS that is confined to the uterus and fully removed generally carries a favourable long-term outlook, and many women do very well for many years. High-grade ESS and undifferentiated uterine sarcoma carry a more guarded outlook, with the stage at diagnosis being the most important single factor. These are broad patterns, not predictions for any one person — your own outlook is shaped by your tumour, its molecular features, and how completely it was removed.

A characteristic of low-grade ESS is its tendency to recur late — sometimes five, ten, or even more years after surgery. This is why follow-up does not stop after a couple of clear scans. Long-term surveillance with clinical review and imaging is part of the plan, and when low-grade disease does recur, it is often still treatable — frequently with further surgery and a switch or escalation of hormone therapy, because the disease usually remains hormone-sensitive. Late recurrence is not the same as treatment failure; it is a known behaviour that is managed, not feared.

Indicative Cost in Hyderabad

Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.

Why Patients Choose CION for Endometrial Stromal Sarcoma Care

ESS is rare and easily mislabelled. Here is why women across Telangana trust CION to get the diagnosis — and the treatment — right.

Get Your ESS Diagnosis Confirmed and Your Plan Made

With a disease this rare and this easily mislabelled, a specialist second opinion changes the plan more often than you might expect. If you have an ESS report — or a fast-growing mass that hasn't been explained — talk to us first.